Skip to main content
SpringerLink
Log in
Book cover

Pharmacogenomics and Personalized Medicine pp 1–26Cite as

Challenges, Opportunities, and Evolving Landscapes in Pharmacogenomics and Personalized Medicine

An Industry Perspective

  • Protocol

Part of the book series: Methods in Pharmacology and Toxicology ((MIPT))

Abstract

Pharmacogenomics (PGx) is the study of the genetic basis of variability among individuals in response to drugs. It is the newest discipline of medicine and is becoming a very active area of research, with the pharmaceutical industry gaining experience applying it, integrating it into the drug development process, and also learning to better manage the expectations of the medical community. Personalized medicine (PM), based on the genetic makeup of a patient, may result in not only an improved therapeutic response but also a clinically important reduction in adverse drug reactions. The experience to date is mixed, with a few successes but many frustrations. This chapter provides an industry perspective on the emergence of the field of PGx focusing on the more mature DNA technologies. Specifically, the chapter will: (1) give a brief description of the history of PGx, (2) provide definitions of key terms, (3) look at the elements in the current healthcare and commercial environment that are driving us to personalized medicine, (4) consider the challenges (strategic/commercial, scientific, regulatory, implementation) that need to be addressed to make PGx and personalized medicine (PM) a reality, and finally, (4) provide a few practical recommendations from an industry perspective for improved success in this area.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Garrod AE (1902) The incidence of alkaptonuria. A study in chemical individuality. Lancet, pp 1616–1620

    Google Scholar 

  2. Haldane, JBS (1949) Disease and evolution. Ric Sci 19:68–75

    Google Scholar 

  3. Kalow W (2006) Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine. Pharmacogenomics J 6:162–165

    Article  CAS  PubMed  Google Scholar 

  4. Kalow W (1956) Familial incidence of low pseudocholinesterase level. Lancet pp 576

    Google Scholar 

  5. Bonicke R, Lisboa BP (1957) Über die Erbbedingtheit der intraindividuellen Konstanz der Isoniazidausscheidung beim Menchen. Naturwissenschaften 44:314–320

    Article  CAS  Google Scholar 

  6. Vogel F (1959) Moderne Probleme der Humangenetic. Ergeb Inn Med Kinderheikd 12:52–125.

    Google Scholar 

  7. Mahgoup A, Dring L, Idle JR, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrosiquine in man. Lancet 2:584–586

    Article  Google Scholar 

  8. Eichelbaum M, Spanbrucker N, Steinke B, Dengler HJ (1997) Defective N-oxydation of spartein in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16:183–187

    Article  Google Scholar 

  9. Maraz D, Legrand M, Sabbagh N et al. (1997) Polymorphism of the cytochrome P450 CYP2D6 in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evaluation. Pharmacogenetics 7:197–202

    Google Scholar 

  10. Kalow W (2001) Interethnic differences in drug response. In: Kalow W, Meyer UA, Tyndale RF (eds) Pharmacogenomics. Marcel Dekker Inc., New York, pp 109–134

    Google Scholar 

  11. Weber WW (2001) Pharmacogenetics-receptors. In: Kalow W, Meyer UA, Tyndale RF (eds) Pharmacogenomics. Marcel Dekker Inc., New York, pp 51–80

    Google Scholar 

  12. Ho RH, Kim RB (2005) Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78:260–277

    Article  CAS  PubMed  Google Scholar 

  13. Bondy B (2005) Pharmacogenetics in depression and antidepressants. Dialogues Clin Neurosci 7:223–230

    PubMed  Google Scholar 

  14. Kalow W (1982) Ethnic differences in drug metabolism. Clin Pharmacokinet 7:373–400

    Article  CAS  PubMed  Google Scholar 

  15. Dickins M, Ducker G (2001) Drug disposition: to phenotype or genotype. Int J Pharm Med 15:70–73.

    Google Scholar 

  16. Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapies. Science 206:487–491

    Article  Google Scholar 

  17. Fellay J et al. (2002) Response to antiretroviral treatment in HIV-1 infected individuals with allele variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359:30–36.

    Article  CAS  PubMed  Google Scholar 

  18. Dubinsky M et al. (2000) Pharmacogenomics and metabolite measurement for 6-mercaptopu-rine therapy in inflammatory bowel disease. Gastroenterology 118:705–713

    Article  CAS  PubMed  Google Scholar 

  19. U.S. FDA. Guidance for industry: pharmacogenomic data submissions. http://www.fda.gov/cder/guidance/6400fnl.pdf. Accessed July 25, 2007

  20. Farlow MR, Lahiri DK, Poirier J, Davignon J, Hui S (1996) Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann N Y Acad Sci. 802:101–110

    Article  CAS  PubMed  Google Scholar 

  21. Herceptin product label. http://www.fda.gov/cder/biologics/products/trasgen092598.htm. Accessed July 25, 2007

  22. Erbitux product label. http://www.fda.gov/Cder/drug/infopage/erbitux/default.htm Accessed February 12, 2004

  23. Gleevec revised product label. http://www.fda.gov/CDER/drug/infopage/gleevec/default.htm. Accessed October 30, 2006

  24. Tarceva product label. http://www.fda.gov/cder/foi/label/2004/021743lbl.pdf. Accessed July 25, 2007

  25. Camptosar product label. http://www.fda.gov/cder/foi/label/2006/020571s030lbl.pdf. Accessed July 25, 2007

  26. Strattera product label. http://www.fda.gov/cder/foi/label/2007/021411s004s012s013s015s021lbl.pdf. Accessed July 25, 2007

  27. Purinethol product label. http://www.fda.gov/cder/foi/label/2004/09053s024lbl.pdf. Accessed July 25, 2007

  28. Coumadin product label. http://www.fda.gov/cder/foi/label/2006/009218s102lbl.pdf. Accessed July 25, 2007

  29. Centre for Medicines Research (CMR) International Ltd. (2006) NME output lifts from 20 year low. Thomson Scientific KnowledgeLink Newsletter

    Google Scholar 

  30. Tufts Center for the Study of Drug Development, Outlook 2006

    Google Scholar 

  31. U.S. FDA. Innovation or stagnation: challenge and opportunity on the critical path to new medical products. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html. Accessed on July 25, 2007

  32. Vioxx withdrawal. Merck press release. http://www.vioxx.com/vioxx/documents/english/vioxx_press_release.pdf.

  33. Bill S.3822. Genomics and personalized medicine act of 2006. Introduced in U.S. Senate by Barak Obama

    Google Scholar 

  34. Kim MJ et al. (2008) Pharmacogenomics: the regulatory environment and labeling implication. In: Cohen N (ed) Pharmacogenomics and personalized medicine. Humana Press (Springer) Chapter 3

    Google Scholar 

  35. Gutman S, Hackett J (2006) Search for shortcuts on the critical path to market: US FDA perspectives from the diagnostic side. Pharmacogenomics 7(8):1223–1227

    Article  PubMed  Google Scholar 

  36. EMEA Pharmacogenomics Working Party. http://www.emea.europa.eu/pdfs/human/pharmacogenetics/10159204en.pdf.

  37. Guiding principles: processing joint FDA-EMEA voluntary genomic data submissions (VGDSs) within the framework of the confidentiality arrangement. http://www.emea.europa.eu/pdfs/general/direct/pr/FDAEMEA.pdf.

  38. ICH terminology in pharmacogenomics (E15). http://www.fda.gov/cder/guidance/7619dft.pdf.

  39. Arcoxia non–approvable. http://www.merck.com/newsroom/press_releases/research_and_development/2007_0427.html.

  40. PhRMABiomarkerConsortium. http://www.innovation.org/index.cfm/NewsCenterBriefings/The_Biomarkers_Consortium.

  41. Predictive Safety Testing Consortium. http://www.fda.gov/bbs/topics/news/2006/NEW01337.html.

  42. Serious Adverse Event Consortium (www.saeconsortium.org).

  43. Industry-Pharmacogenomics Working Group. http://www.i-pwg.org/cms/

  44. Spear B, Heath-Chiozzi M, Barnes D, Cheeseman K, Shaw P, Campbell D (2001) Termi no-logy for sample collection in clinical genetic studies. Pharmacogenomics J 1:101–3

    Article  Google Scholar 

  45. Anderson C, Gomez- Mancilla B, Spear B et al. (2002) Elements of informed consent for phar-macogenetic research: perspective of the Pharmacogenetics Working Group. Pharmacogenomics J 2(5):284–92

    Article  CAS  PubMed  Google Scholar 

  46. Renegar G, Webster C, Stuerzebecher S et al. (2006) Returning genetic research results to individuals: points to consider. Bioethics 20(1):24–36

    Article  PubMed  Google Scholar 

  47. Personalized Medicine Coalition. http://www.personalizedmedicinecoalition.org/communications/overview.php.

  48. U.S. FDA. Genomics at FDA: table of valid genomic biomarkers in the context of approved drug labels. http://www.fda.gov/cder/genomics/genomic_biomarkers_table.htm. Accessed July 25, 2007

  49. Lesko LJ. (2007) Personalized medicine: elusive dream or imminent reality? Clin Pharmacol Ther 81:807–816

    Article  CAS  PubMed  Google Scholar 

  50. Point of Care Diagnostic Dr Nakamura accessed at http://www.twt.com/company/press-releases/2006/March_2_2006.htm.

  51. National Coalition for Health Professional Education in Genetics (NCHPEG). http://www.nchpeg.org/.

  52. Council for International Organizations of Medical Sciences (CIOMS) (2002) International Ethical Guidelines for Biomedical Research Involving Human Subjects accessed at http://www.cioms.ch/frame_guidelines_nov_2002.htm.

  53. Nuffield council report on bioethics of pharmacogenetics. http://www.nuffieldbioethics.org/filelibrary/paf1/pharmacogenetics_report.pdf.

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacogenomics, Johnson and Johnson Pharmaceutical Research and Development, L.L.C., Raritan, NJ

    Nadine Cohen

  2. mmercial Marketing, Johnson and Johnson Pharmaceutical Research and Development, L.L.C., Raritan, NJ

    Theresa Frangiosa

Authors
  1. Nadine Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Theresa Frangiosa
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Johnson and Johnson Pharmaceutical Research and Development, L.L.C., Raritan, NJ, USA

    Nadine Cohen

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Cohen, N., Frangiosa, T. (2008). Challenges, Opportunities, and Evolving Landscapes in Pharmacogenomics and Personalized Medicine. In: Cohen, N. (eds) Pharmacogenomics and Personalized Medicine. Methods in Pharmacology and Toxicology. Humana Press. https://doi.org/10.1007/978-1-59745-439-1_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-439-1_1

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-04-6

  • Online ISBN: 978-1-59745-439-1

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation